Zhaoke Ophthalmology Ltd (06622.HK)価格

Zhaoke Ophthalmology Ltd. operates as holding company, which engages in the provision of ophthalmic pharmaceuticals. The company is headquartered in Guangzhou, Guangdong and currently employs 270 full-time employees. The company went IPO on 2021-04-29. The product pipelines primarily include NVK002 (Atropine) for myopia, CsA Ophthalmic Gel for DED and TAB014 (Bevacizumab) for wAMD. The products are primarily uses to treat eye diseases across both the front and the back of the eye, including dry eye disease (DED), myopia, presbyopia, wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), glaucoma and corneal epithelial dysfunction (CED). The firm conducts its business in the domestic market and overseas markets.